Fibrillar Beta-amyloid Induces Microglial Phagocytosis, Expression of Inducible Nitric Oxide Synthase, and Loss of a Select Population of Neurons in the Rat CNS in Vivo

Overview

Journal J Neurosci

Specialty Neurology

Date 1998 Apr 18

PMID 9482801

Citations 112

Authors

D T Weldon

S D Rogers

J R Ghilardi

M P Finke

J P Cleary

E OHare

W P Esler

J E Maggio

P W Mantyh

Affiliations

Soon will be listed here.

Abstract

To determine the stability of beta-amyloid peptide (Abeta) and the glial and neuronal changes induced by Abeta in the CNS in vivo, we made single injections of fibrillar Abeta (fAbeta), soluble Abeta (sAbeta), or vehicle into the rat striatum. Injected fAbeta is stable in vivo for at least 30 d after injection, whereas sAbeta is primarily cleared within 1 d. After injection of fAbeta, microglia phagocytize fAbeta aggregates, whereas nearby astrocytes form a virtual wall between fAbeta-containing microglia and the surrounding neuropil. Similar glial changes are not observed after sAbeta injection. Microglia and astrocytes near the injected fAbeta show a significant increase in inducible nitric oxide synthase (iNOS) expression compared with that seen with sAbeta or vehicle injection. Injection of fAbeta but not sAbeta or vehicle induces a significant loss of parvalbumin- and neuronal nitric oxide synthase-immunoreactive neurons, whereas the number of calbindin-immunoreactive neurons remains unchanged. These data demonstrate that fAbeta is remarkably stable in the CNS in vivo and suggest that fAbeta neurotoxicity is mediated in large part by factors released from activated microglia and astrocytes, as opposed to direct interaction between Abeta fibrils and neurons.

Citing Articles

The Role of CXCR3 in Nervous System-Related Diseases.

Wang F, Guo B, Jia Z, Jing Z, Wang Q, Li M Mediators Inflamm. 2024; 2024:8347647.

PMID: 39429695 PMC: 11488998. DOI: 10.1155/2024/8347647.

Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States.

Kuhn M, Proctor E Proteins. 2024; .

PMID: 39219300 PMC: 11871049. DOI: 10.1002/prot.26723.

Microglia specific deletion of miR-155 in Alzheimer's disease mouse models reduces amyloid-β pathology but causes hyperexcitability and seizures.

Aloi M, Prater K, Sanchez R, Beck A, Pathan J, Davidson S J Neuroinflammation. 2023; 20(1):60.

PMID: 36879321 PMC: 9990295. DOI: 10.1186/s12974-023-02745-6.

A Function of Amyloid-β in Mediating Activity-Dependent Axon/Synapse Competition May Unify Its Roles in Brain Physiology and Pathology.

Huang Z J Alzheimers Dis. 2023; 92(1):29-57.

PMID: 36710681 PMC: 10023438. DOI: 10.3233/JAD-221042.

The Protective Effect of CBD in a Model of In Vitro Ischemia May Be Mediated by Agonism on TRPV2 Channel and Microglia Activation.

Lana D, Landucci E, Mazzantini C, Magni G, Pellegrini-Giampietro D, Giovannini M Int J Mol Sci. 2022; 23(20).

PMID: 36292998 PMC: 9603301. DOI: 10.3390/ijms232012144.

References

Mattson M, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel R . beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992; 12(2):376-89. PMC: 6575616. View

JARRETT J, Berger E, Lansbury Jr P . The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry. 1993; 32(18):4693-7. DOI: 10.1021/bi00069a001. View

Wisniewski T, Castano E, Golabek A, Vogel T, Frangione B . Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994; 145(5):1030-5. PMC: 1887417. View

Yan S, Chen X, Fu J, Chen M, Zhu H, Roher A . RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996; 382(6593):685-91. DOI: 10.1038/382685a0. View

Kelly J, Furukawa K, Barger S, Rengen M, Mark R, Blanc E . Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons. Proc Natl Acad Sci U S A. 1996; 93(13):6753-8. PMC: 39099. DOI: 10.1073/pnas.93.13.6753. View

Mrak R, Sheng J, Griffin W . Glial cytokines in Alzheimer's disease: review and pathogenic implications. Hum Pathol. 1995; 26(8):816-23. PMC: 3903413. DOI: 10.1016/0046-8177(95)90001-2. View

Canning D, McKeon R, DeWitt D, Perry G, Wujek J, Frederickson R . beta-Amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp Neurol. 1993; 124(2):289-98. DOI: 10.1006/exnr.1993.1199. View

Selden N, Geula C, Hersh L, Mesulam M . Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease. Neuroscience. 1994; 60(3):621-36. DOI: 10.1016/0306-4522(94)90491-x. View

Sanan D, Weisgraber K, Russell S, Mahley R, Huang D, Saunders A . Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994; 94(2):860-9. PMC: 296168. DOI: 10.1172/JCI117407. View

10.

Yankner B, Duffy L, Kirschner D . Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science. 1990; 250(4978):279-82. DOI: 10.1126/science.2218531. View

11.

Cummings B, Cotman C . Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 1995; 346(8989):1524-8. DOI: 10.1016/s0140-6736(95)92053-6. View

12.

Evans K, Berger E, Cho C, Weisgraber K, Lansbury Jr P . Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci U S A. 1995; 92(3):763-7. PMC: 42700. DOI: 10.1073/pnas.92.3.763. View

13.

Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L . Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991; 349(6311):704-6. DOI: 10.1038/349704a0. View

14.

Selkoe D . Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol. 1994; 53(5):438-47. DOI: 10.1097/00005072-199409000-00003. View

15.

Nishiyama E, Ohwada J, Iwamoto N, Arai H . Selective loss of calbindin D28K-immunoreactive neurons in the cortical layer II in brains of Alzheimer's disease: a morphometric study. Neurosci Lett. 1993; 163(2):223-6. DOI: 10.1016/0304-3940(93)90388-2. View

16.

Pike C, Walencewicz A, Glabe C, Cotman C . Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol. 1991; 207(4):367-8. DOI: 10.1016/0922-4106(91)90014-9. View

17.

Harrigan M, Kunkel D, Nguyen L, Malouf A . Beta amyloid is neurotoxic in hippocampal slice cultures. Neurobiol Aging. 1995; 16(5):779-89. DOI: 10.1016/0197-4580(95)00095-v. View

18.

Brosnan C, Battistini L, Raine C, Dickson D, Casadevall A, Lee S . Reactive nitrogen intermediates in human neuropathology: an overview. Dev Neurosci. 1994; 16(3-4):152-61. DOI: 10.1159/000112102. View

19.

Haga S, Ikeda K, Sato M, Ishii T . Synthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 1993; 601(1-2):88-94. DOI: 10.1016/0006-8993(93)91698-r. View

20.

Giulian D, Haverkamp L, Li J, Karshin W, Yu J, Tom D . Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int. 1995; 27(1):119-37. DOI: 10.1016/0197-0186(95)00067-i. View